TIDMDEST
RNS Number : 2919P
Destiny Pharma PLC
18 October 2021
Destiny Pharma plc
("Destiny Pharma" or "the Company")
Major US hospital-based clinical trial highlights benefit of
nasal decolonization to reduce ICU infections caused by
Staphylococcus aureus
Strong support for potential of XF-73 nasal product
as alternative to mupirocin
Brighton, United Kingdom - 18 October 2021 - Destiny Pharma
(AIM: DEST), a clinical stage biotechnology company focused on the
development of novel medicines to prevent life threatening
infections, notes the important study report presented at the
leading international conference, IDWeek virtual meeting which took
place on 30 September - 3 October 2021.
The Phase 4 study[1] was the largest ever of this type, with
over 300,000 patients which explored the link between
Staphylococcus aureus decolonisation and Intensive Care Units (ICU)
infection rates. S.aureus remains a formidable infection-causing
pathogen in the ICU and is the primary bacterial pathogen causing
ICU infections in the USA, responsible for 23% of all infections
and nearly half (44%) of which are caused by the multi-antibiotic
resistant strain, MRSA.
The study, Swap Out Trial, was a 4-year project led by the
renowned hospital infection expert, Professor Susan Huang
(Professor of Infectious Diseases at the University of California
Irvine School of Medicine) in coordination with Healthcare
Corporation America and support from the US Government's Centers
for Disease Control and Prevention (CDC). The study evaluated over
300,000 patients in 233 US ICU and compared levels of infection
after the use of the current leading treatment, a nasal
decolonisation antibiotic ointment - mupirocin - against a nasal
antiseptic, iodophor. The main conclusion was that overall the
nasal antibiotic mupirocin was shown to be superior for the
reduction of S.aureus clinical cultures compared to the nasal
antiseptic iodophor (p< 0.001).
The study has positive implications for Destiny Pharma's novel
XF-73 nasal gel which is being developed as a nasal S. aureus
decolonisation medicine:
-- The issue of mupirocin resistance remains a global concern
and products which are as effective but do not cause Antimicrobial
Resistance (AMR) are urgently needed
-- The study indicates that the nasal antiseptic iodophor is not
as effective as mupirocin and underlines the significant market
opportunity for XF-73 as a much-needed new medicine for hospitals
to help prevent infections in the ICU and the post-surgical
setting
-- XF-73 nasal gel has the potential to deliver a Target Product
Profile (TPP) with significant advantages over mupirocin
including;
-- Effective nasal S. aureus decolonisation in 24 hours compared
to 5 days for mupirocin (March 2021 Phase 2 data success)
-- Significantly quicker decolonisation and thus more cost-effective
-- Ultra-rapid bactericidal drug, novel mechanism of action and
no propensity for resistance seen to its potent activity against
MRSAs
-- Easy to use, patient compliance, non-irritant nasal gel formulation
-- Low cost of goods enabling pragmatic pricing/easier reimbursement
Destiny Pharma is currently in regulatory discussions concerning
the appropriate Phase 3 clinical study design to enable marketing
approval for XF-73 nasal gel in Europe and the USA.
Neil Clark, Chief Executive Officer of Destiny Pharma, said:
"This large, multi-year study clearly supports the value of nasal
treatment to remove S. aureus and shows yet again the significant
interest in improving the efficacy of nasal decolonisation because
it is a major contributor to delivering a reduction in
post-surgical S. aureus infections.
"Destiny Pharma's XF-73 nasal gel is focused on delivering a
novel decolonisation treatment and following the excellent Phase 2
clinical data, reported earlier in 2021, we remain committed to
finalising our Phase 3 plans and bringing XF-73 to the hospital
market to meet this clear and substantial clinical need. The
Company believes strongly that XF-73 has the potential to provide a
major step change and improvement in S. aureus decolonisation
compared to mupirocin; XF-73 is faster acting with a broader
antimicrobial action. Furthermore, XF-73 does not generate
resistance (AMR), which remains a major concern with the continuing
use of mupirocin."
-END-
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
Optimum Strategic Communications
Mary Clark / Hollie Vile / Manel Mateus
destinypharma@optimumcomms.com
+44 (0) 208 078 4357
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0)20 3705 9321
MC Associates AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-0
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology
company focused on the development of novel medicines that can
prevent life-threatening infections. Its pipeline has novel
microbiome-based biotherapeutics and XF drug clinical assets
including NTCD-M3, a Phase 3 ready treatment for the prevention of
C. difficile infection (CDI) recurrence which is the leading cause
of hospital acquired infection in the US and also XF-73 nasal gel,
which has recently completed a positive Phase 2b clinical trial
targeting the prevention of post-surgical staphylococcal hospital
infections including MRSA. It is also co-developing SPOR-COV, a
novel, biotherapeutic product for the prevention of COVID-19 and
other viral respiratory infections and has earlier grant funded XF
research projects.
For further information, please visit https://www.destinypharma.com
Forward looking statements
Certain information contained in this announcement, including
any information as to the Group's strategy, plans or future
financial or operating performance, constitutes "forward-looking
statements". These forward looking statements may be identified by
the use of forward-looking terminology, including the terms
"believes", "estimates", "anticipates", "projects", "expects",
"intends", "aims", "plans", "predicts", "may", "will", "seeks"
"could" "targets" "assumes" "positioned" or "should" or, in each
case, their negative or other variations or comparable terminology,
or by discussions of strategy, plans, objectives, goals, future
events or intentions. These forward-looking statements include all
matters that are not historical facts. They appear in a number of
places throughout this announcement and include statements
regarding the intentions, beliefs or current expectations of the
Directors concerning, among other things, the Group's results of
operations, financial condition, prospects, growth, strategies and
the industries in which the Group operates. The directors of the
company believe that the expectations reflected in these statements
are reasonable, but may be affected by a number of variables which
could cause actual results or trends to differ materially. Each
forward-looking statement speaks only as of the date of the
particular statement. By their nature, forward-looking statements
involve risks and uncertainties because they relate to events and
depend on circumstances that may or may not occur in the future or
are beyond the Group's control. Forward looking statements are not
guarantees of future performance. Even if the Group's actual
results of operations, financial condition and the development of
the industries in which the Group operates are consistent with the
forward-looking statements contained in this document, those
results or developments may not be indicative of results or
developments in subsequent periods.
[1] Presentation 4 - 137: Hospital Cluster-Randomized Trial of Mupirocin-Chlorhexidine vs Iodophor-Chlorhexidine for Universal Decolonization in Intensive Care Units (ICUs) (Mupirocin Iodophor Swap Out Trial).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCKZMMGKKGGMZM
(END) Dow Jones Newswires
October 18, 2021 02:00 ET (06:00 GMT)
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Destiny Pharma (LSE:DEST)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024